Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Blood (2023) 142 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2023-181628

Published: 2023

Journal Articles

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Antonieta Molero Yordi, Soraya Peralta Garzón, Laura Gallur, Barbara Tazon, Daniel Medina, Victor Navarro Garces, Maria Julia Montoro, Silvia Saumell, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso Pierola, Felipe Prosper, Maria Diez-Campelo, Olga Salamero, Ana Pérez González, Sara Garrido Paniagua, David Valcarcel

Blood (2023) 142 (Supplement 1): 6457.

https://doi.org/10.1182/blood-2023-185616

Published: 2023

Journal Articles

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Blood (2023) 142 (Supplement 1): 3235.

https://doi.org/10.1182/blood-2023-181698

Published: 2023

Journal Articles

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Blood (2022) 140 (Supplement 1): 9335–9337.

https://doi.org/10.1182/blood-2022-163180

Published: 2022

Journal Articles

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 1592–1594.

https://doi.org/10.1182/blood-2022-169783

Published: 2022

Journal Articles

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Sandra Novoa Jáuregui, Laura Palomo, Ana Pérez, Bárbara Tazón, Maria Julia Montoro, Adoracion Blanco, Silvia Saumell, Laura Gallur, Eugenia Rivero, Sara Garrido, Marc Bosch Schips, Sofia Laura Muzio, Margarita Ortega, Antonieta Molero Yordi, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 6966–6967.

https://doi.org/10.1182/blood-2022-168705

Published: 2022

Journal Articles

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Marc Bosch Schips, Julia Montoro, Félix López Cadenas, Alba Mesa, Víctor Navarro Garcés, Ana Pérez, Laura Gallur, Silvia Saumell, Mayda Navarrete, Margarita Ortega, Bárbara Tazón, Antonieta Molero, Olga Salamero, Sandra Novoa Jáuregui, Sofia Laura Muzio, Francesc Bosch, David Valcárcel

Blood (2022) 140 (Supplement 1): 12308–12310.

https://doi.org/10.1182/blood-2022-157434

Published: 2022

Journal Articles

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Soraya Peralta, Laura Gallur, Bárbara Tazón, Víctor Navarro Garcés, Silvia Saumell, Maria Julia Montoro, Olga Salamero, Ana Pérez González, Sara Garrido, Maria Sola, Tamara Jimenez, Félix López Cadenas, Teresa Ezponda, Ana Alfonso-Pierola, Lídia Altimiras, Maria Diez-Campelo, Felipe Prosper, David Valcárcel

Blood (2022) 140 (Supplement 1): 4024–4025.

https://doi.org/10.1182/blood-2022-163188

Published: 2022

Journal Articles

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Antonieta Molero Yordi, Bárbara Tazón, Laura Gallur, Silvia Saumell, Tamara Jimenez, Teresa Ezponda, Maria Julia Montoro, Félix López Cadenas, Lídia Altimiras, Carla Sánchez Ruiz, Ana Alfonso, Olga Salamero, Ana Pérez, Soraya Peralta, Maria Diez-Campelo, Felipe Prosper, Francesc Bosch, David Valcarcel

Blood (2021) 138 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2021-150104

Published: 2021

Journal Articles

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Blood (2019) 134 (Supplement_1): 2612.

https://doi.org/10.1182/blood-2019-129153

Published: 2019

Journal Articles

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

Juan C Nieto, PhD, Elisa Roldan, MD, Isabel Jiménez, MSc, Laura Fox, Júlia Carabia, PhD, Guillermo Orti, Lluis Puigdefàbregas, Laura Gallur, Gloria Iacoboni, MD, Priyanka Raheja, Ana Perez, Olga Salamero, MD, Carlos Palacio, David Valcarcel, MD, Marta Crespo, PhD, Francesc Bosch, MD, Pere Barba, MD

Blood (2018) 132 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2018-99-114887

Published: 2018

Journal Articles

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

Julia Montoro, Helena Pomares, Brayan Merchan, Antonieta Molero, Silvia Saumell, Esther Alonso, Mónica Fernández, Laura Gallur, Javier Grau, Olga Salamero, Adoración Blanco, Anna Varela, Elisa Roldán, Anna Sureda, Francesc Bosch, Montserrat Arnan Sangerman, David Valcarcel

Blood (2017) 130 (Supplement 1): 5306.

https://doi.org/10.1182/blood.V130.Suppl_1.5306.5306

Published: 2017

Journal Articles

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2013) 122 (21): 4153.

https://doi.org/10.1182/blood.V122.21.4153.4153

Published: 2013

Journal Articles

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Noelia Purroy, MD, Pau Abrisqueta, MD, Eva Calpe, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3868.

https://doi.org/10.1182/blood.V120.21.3868.3868

Published: 2012

Journal Articles

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

Noelia Purroy, Juan Bergua, Laura Gallur, MD, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez

Blood (2011) 118 (21): 593.

https://doi.org/10.1182/blood.V118.21.593.593

Published: 2011

Journal Articles

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Noelia Purroy, MD, Eva Calpe, Pau Abrisqueta, MD, Cecilia Carpio, MD, Carles Palacio, MD, Laura Gallur, MD, Josep Castellvi, MD, Marta Crespo, PhD, Francesc Bosch, MD, PhD

Blood (2011) 118 (21): 2844.

https://doi.org/10.1182/blood.V118.21.2844.2844

Published: 2011

Journal Articles

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Angel Guerra-Moreno, Carlos Palacio, MD, Noemí Martínez-Morgado, Margarita Ortega, Maida Navarrete, M.D., Carmen Sánchez-Morata, M.D., Laura Gallur, MD, Javier Bueno, Teresa Vallespi, MD.PhD.

Blood (2009) 114 (22): 4424.

https://doi.org/10.1182/blood.V114.22.4424.4424

Published: 2009

Journal Articles

Influence of the FCGR3A-158 V/F and FCGR2A-131 H/R Polymorphism on the Response to Rituximab Therapy in Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia.

F. Javier Peñalver, Carlos Vilches, Alberto Albarez-Larran, Isidro Jarque, M.J. Rodriguez, Laura Gallur, Dolores Caballero, Javier Castaño, M.J. Fernandez, J. Rafael Cabrera

Blood (2007) 110 (11): 2097.

https://doi.org/10.1182/blood.V110.11.2097.2097

Published: 2007

Journal Articles

Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.

Andres Palacios, Mayda Navarrete, Laura Gallur, Javier Zuazu, Cristina Barrenetxea, Eva Sanchez, Andres Lopez

Blood (2006) 108 (11): 4707.

https://doi.org/10.1182/blood.V108.11.4707.4707

Published: 2006

Journal Articles

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Andrés López, MD, Laura Gallur, MD, Andrés Palacios, MD, Mayda Navarrete, MD, Carmen Ruiz-Marcellán, MD, Josep Castellví, MD, Santiago Ramón y Cajal, MD, Antonio Juliá, MD

Blood (2005) 106 (11): 4716.

https://doi.org/10.1182/blood.V106.11.4716.4716

Published: 2005

NARROW

A Novel Machine-Learning Model to Predict Early Relapse in Mantle Cell Lymphoma (MCL)

Bone Marrow Cytokines Concentrations in Myelodysplastic Neoplasms: Its Correlation with the Immune Populations and Clonal Hematopoiesis

Clinical Impact of the New Bone Marrow Blasts Cutoff Defined By the International Classification Consortium (ICC) in Myeloid Neoplasms with Mutated TP53 gene

Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)

Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression

Microenvironment Profiling in Myelodysplastic Syndromes and Its Relationship to Clonal Hematopoiesis and Disease Progression

Acute Myeloid Leukemia with Myelodisplasia-Related Changes (AML-MRC) Defined Only By Morphological Findings May Not Represent a Poor Prognosis AML

Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab

An IPSS-R Cutpoint of 3 Stratified Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) Patients (pts) into Two Risk Groups

The Co-Culture Of Primary CLL Cells With Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes The Proliferation Of Chemoresistant CLL Cells Phenotypically Comparable To Those From The Proliferative Centers

YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection

Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group

ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Influence of the FCGR3A-158 V/F and FCGR2A-131 H/R Polymorphism on the Response to Rituximab Therapy in Immune Thrombocytopenic Purpura and Autoimmune Hemolytic Anemia.

Re-Treatment with Rituximab Plus Chemotherapy in Patients with Aggressive Lymphoma Treated Previously with CHOP or CHOP-Like Combinations Plus Rituximab.

Dose Adjusted EPOCH Chemotherapy Plus Rituximab Combination (DA-R-EPOCH), an Effective Upfront Therapy for Patients with Poor-Risk Aggressive B-Cell Lymphomas. Results of a Pilot Study in a Single Center.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only